Abstracts - faqs.org

Abstracts

Business, international

Search abstracts:
Abstracts » Business, international

LUPIN LABORATORIES HOLDS 40% SHARE IN ANTI-TB FORMULATIONS MARKET

Article Abstract:

Lupin Laboratories, in which Mr Desh Bandhu Gupta and associates hold 75 percent stake, is the largest manufacturer of anti-tuberculosis drugs. It holds 40 percent share in the formulations segment. The promoter is planning to divest 10 percent of his stake in the company. It is shortly acquiring Eli Lilly's cephalosporin unit in Puerto Rico. It also plans to buy out a unit from Max-GB in the domestic market. It plans to target generic market in the West with cefotaxime, ceftriaxone, ceftazidine, cefaclor, cefalexin and cefadroxyl. For 1997-98, the company has posted a net profit of $8.1 million on sales of $164 million. (gs)

Comment:

Is the largest manufacturer of anti-tuberculosis drugs, holding 40% share in the formulations segment

Publisher: Bennett, Coleman & Co. Ltd.
Publication Name: Economic Times
Subject: Business, international
ISSN: 0013-0389
Year: 1998
Sales & consumption, Tuberculostatic Preparations, Antitubercular agents, Article, Lupin Laboratories

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


TBL IN TALKS WITH MNCS TO SELL TRANSGENE VACCINE

Article Abstract:

Transgene Biotek Ltd (TBL), a Hyderabad-based vaccine manufacturing company, is negotiating with certain multinational drug companies to sell its 100 percent subsidiary - Transgene Vaccine. TBL specialises in making Hepatitis-B vaccine. TBL has appointed India Securities to find a buyer. TBL is currently setting up facilities to make three million doses of Hepatitis B vaccines in Hyderabad. TBL, however, has decided to sell the business only if it gets a suitable offer. (um)(psr)

Comment:

Transgene Biotek Ltd (TBL), a Hyderabad-based vaccine manufacturing company, is negotiating with certain multinational drug companies to sell its 100 percent subsidiary - Transgene Vaccine.

Publisher: Bennett, Coleman & Co. Ltd.
Publication Name: Economic Times
Subject: Business, international
ISSN: 0013-0389
Year: 1999
Asset sales & divestitures, Vaccines for Human Use, Vaccines, Transgene Biotek Ltd, Transgene Vaccine

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA



Subjects list: India
Similar abstracts:
  • Abstracts: HMR PLANS TO DOUBLE VACCINE SALES INDIA ONLINE SALES SEEN AT $160 MILLION BY 2001
  • Abstracts: HSBC TRADE PLANS TO OFFER FACTORING SERVICES IN S INDIA. SUMAN MOTELS RECORDS 12% RISE IN H1 NET
  • Abstracts: RINL PLANNING EXPORT OF FURNACE SLAG LAFARGE IN PACT WITH TATA STEEL FOR SLAG SUPPLY. RINL ANCILLARIES DO WELL
  • Abstracts: RPG PLANS TO BE FIRST TO MAKE VITAMIN B2 MacNEAL-SCHWENDLER TO SET UP INDIAN UNIT. NAL FLIES WORLD'S FIRST WANKEL MICROLIGHT
  • Abstracts: MSIL PLANS TO ENTER CONSUMER DURABLE RETAILING BUSINESS REAL ESTATE ADVISOR JLW PLANS OFFICE IN CHENNAI. DELTMAL SHOES SET TO START PRODUCTION IN OCTOBER
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.
Some parts © 2025 Advameg, Inc.